Status:
COMPLETED
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Lead Sponsor:
Pfizer
Conditions:
Metastatic Breast Cancer
Advanced Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following stud...
Eligibility Criteria
Inclusion
- Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Exclusion
- See inclusion criteria
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT00428220
Start Date
July 1 2007
End Date
September 1 2014
Last Update
June 27 2019
Active Locations (113)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States, 30322
2
Investigational Drug Service
Atlanta, Georgia, United States, 30322
3
The Emory Clinic
Atlanta, Georgia, United States, 30322
4
Loyola University Medical Center
Maywood, Illinois, United States, 60153